These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20952747)

  • 21. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
    Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
    Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
    Miederer M; Weber MM; Fottner C
    Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [68Ga-DOTA-PET for neuroendocrine tumours].
    Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
    Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging of NETs with PET radiopharmaceuticals.
    Ambrosini V; Tomassetti P; Franchi R; Fanti S
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear Medicine Imaging of Neuroendocrine Tumors.
    Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
    Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
    Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
    J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
    Li S; Beheshti M
    Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical studies of SPECT and PET tracers for NET.
    Brom M; Boerman O; Gotthardt M; Oyen WJ
    PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience.
    Naswa N; Bal CS
    Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
    Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
    Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radio-guided surgery in neuroendocrine tumors.
    Gulec SA; Baum R
    J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear medicine procedures in the diagnosis of NET: a historical perspective.
    Maffione AM; Karunanithi S; Kumar R; Rubello D; Alavi A
    PET Clin; 2014 Jan; 9(1):1-9. PubMed ID: 25029929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gallium-68 PET: a new frontier in receptor cancer imaging.
    Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
    Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
    De Martino MC; Hofland LJ; Lamberts SW
    Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.
    De Dosso S; Treglia G; Pascale M; Tamburello A; Santhanam P; Kroiss AS; Pereira Mestre R; Saletti P; Giovanella L
    Endocrine; 2019 Jun; 64(3):456-468. PubMed ID: 31004334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
    Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.